Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.Moderna, Inc. (NASDAQ: MRNA ) has seen steady weakness in its share price as demand for its COVID-19 vaccine has declined. The company has a $20 billion m ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have lost significantly in the past couple of years due to declining sales amid low demand for the vaccine. In the past month, MRNA stock fell more than 20% after management provided an update on its business outlook for the next four years. It also announced plans to slash its research and development (R&D) budget during this period. In the past month, the stock has underperformed the industry's 2.3% ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%. During ...

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "mRNA Cancer Vaccines and Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA cancer vaccines and therapeutics market size has grown rapidly in recent years. It will grow from $52.85 billion in 2023 to $61.52 billion in 2024 at a compound annual growth rate (CAGR) of 16.4%. The mRNA cancer vaccines and therapeutics market size is expected to see rapid growth in the next few years. It will grow to $113.41 billion ...

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio? Also Read: Photo by rafapress via Shutterstock ...

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. So what: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: ...

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Moderna, Inc. (MRNA) announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its investigational mRNA norovirus vaccine candidate, mRNA-1403, in the United States. The randomized, placebo-controlled phase III study will evaluate the safety, efficacy and immunogenicity of mRNA-1403 to prevent moderate-to-severe acute gastroenteritis caused by norovirus. Recruitment of participants in the pivotal Nova 301 study across the world has also begun. Shares of Moderna have ...

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to guide the company's strategic direction, this also signals Dr. Langer's strong belief in the company's miss ...